US biotech Gilead Sciences (Nasdaq: GILD) has received European marketing authorization for two doses of Descovy (emtricitabine and tenofovir alafenamide), a fixed-dose combination for the treatment of HIV-1 infection.
It is indicated in the European Union for the treatment of adults and adolescents in combination with other HIV antiretroviral agents.
The authorization, allowing for the marketing of Descovy in all 28 countries of the European Union, is based on a Phase III HIV clinical program evaluating F/TAF in combination with other antiretroviral agents in treatment naïve, virologically suppressed, renally impaired and adolescent patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze